Bristol-Myers Squibb Delivers Solid Q2 Results with Strong Portfolio Growth
Highlights
- Company revenues: $12.3B (+17% YoY)
- Global sales of Opdivo: $2.6B (+7%)
- Reblozyl global sales: $568M, over $1B year-to-date (+30% in the U.S.)
- Breyanzi revenues: $344M (+122%)
- Camzyos global sales: $260M (+86%)
- Eliquis global sales: $3.7B (+6%)
- Cobenfy sales: $35M in Q2, $62M year-to-date
- Strong cash position: $13.9B in cash, cash equivalents, and marketable securities
- Increased full-year revenue guidance: $46.5B-$47.5B
Bristol-Myers Squibb (NYSE: BMY) has posted impressive financial results for the second quarter of 2025, marked by robust sales across its growth portfolio, particularly within oncology and hematology. The company's commitment to driving sustainable growth is evident as they report encouraging figures and raise their financial guidance for the year.
Impressive Growth in Oncology and Hematology
Opdivo, the cornerstone of Bristol-Myers Squibb's oncology portfolio, generated global sales of $2.6 billion, a significant 7% increase, further accelerated by promising launches in MSI-high colorectal cancer. Meanwhile, Reblozyl's global revenue reached $568 million, surpassing $1 billion year-to-date, driven by a 30% surge in U.S. sales reflecting its growing acceptance in various anemia-associated indications.
Breyanzi continues to exceed expectations with a staggering 122% revenue growth to $344 million, showcasing strong demand across all indications, and highlighting improvements in its manufacturing success rate and market presence.
Cardiovascular Products Excel
Camzyos demonstrated remarkable demand growth, with global sales climbing 86% to $260 million. With Eliquis enjoying a steady 6% increase in global sales to $3.7 billion, Bristol-Myers Squibb's cardiovascular portfolio reinforces its robust position in a competitive market.
New Products and Strategic Partnerships
Cobenfy, a new entry in their growth portfolio, generated $35 million in Q2 sales and $62 million year-to-date. The company is optimistic about its future, attributing potential growth to physicians' positive feedback and Cobenfy's differentiated profile. In addition, Bristol-Myers Squibb announced a strategic partnership with BioNTech, further cementing their position in immuno-oncology.
Financial Stability and Raised Guidance
The company's financial health is bolstered by a strong cash position of $13.9 billion in cash, cash equivalents, and marketable securities. Reflecting confidence in sustained portfolio strength and performance, Bristol-Myers Squibb has raised its full-year revenue guidance to between $46.5 billion and $47.5 billion.
Bristol-Myers Squibb's second quarter results affirm its strong execution and strategic positioning, driven by a diversified and robust growth portfolio. These developments, coupled with strategic business initiatives, highlight the potential upside for investors looking at the company's future trajectory.